Hepatic Encephalopathy (HE) Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025

The hepatic encephalopathy (HE) therapeutics market share is expected to increase by USD 1 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 6.08%.

This hepatic encephalopathy (HE) therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers hepatic encephalopathy (HE) therapeutics market segmentation by product (NADs, antibiotics, and others) and geography (North America, Europe, Asia, and ROW). The hepatic encephalopathy (HE) therapeutics market report also offers information on several market vendors, including Alfasigma Spa, ASKA Pharmaceutical Co. Ltd., Bausch Health Companies Inc., COSMO PHARMACEUTICALS NV, Cumberland Pharmaceuticals Inc., Horizon Therapeutics Plc, Lupin Ltd., Mallinckrodt Plc, Norgine BV, and Rebiotix Inc. among others.

What will the Hepatic Encephalopathy (HE) Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Hepatic Encephalopathy (HE) Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Hepatic Encephalopathy (HE) Therapeutics Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The availability of patient-focused programs to assist disease management is notably driving the hepatic encephalopathy (HE) therapeutics market growth, although factors such as late and inaccurate diagnosis may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the hepatic encephalopathy (HE) therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Hepatic Encephalopathy (HE) Therapeutics Market Driver

One of the key factors driving growth in the hepatic encephalopathy (HE) therapeutics market in the availability of patient-focused programs to assist disease management. Vendors in the market conduct several programs to help patients manage HE. For instance, Salix conducts the Hepatic Encephalopathy Living Program (H.E.L.P.), which provides support to patients and their caregivers to manage HE. H.E.L.P. provides a 24/7 helpline service that is managed by trained nurses to address queries and make reminder calls about medicine refills and doctor visits. Such programs improve convenience for patients, which increases adherence to therapeutics. The availability of such patient-focused programs to assist with the management of HE will drive the growth of the global HE therapeutics market during the forecast period.

Key Hepatic Encephalopathy (HE) Therapeutics Market Trend

The technological advances is another factor supporting the hepatic encephalopathy (HE) therapeutics market share growth. The adoption of advanced technology to improve the safety profile of the therapeutics used to treat HE is increasing. For instance, the Multi Matrix (MMX) technology, which is offered by COSMO PHARMACEUTICALS, is one such promising development. The MMX technology helps deliver antibiotics directly into the colon. The direct delivery of the drug to the colon helps in preventing the unwanted effects on the beneficial bacterial flora in the GI tract. The controlled release of APIs by the tablet over the colon's length simplifies the application for patients and enables the topical application of APIs to complete a part of the bowel surface, which is inflamed. The MMX technology has the potential to be used for other colon-related diseases. Hence, such technological advances will drive the growth of the global HE therapeutics market during the forecast period.

Key Hepatic Encephalopathy (HE) Therapeutics Market Challenge

The late and inaccurate diagnosis will be a major challenge for the hepatic encephalopathy (HE) therapeutics market during the forecast period. The symptoms of HE are non-specific. They include personality changes, slurred speech, poor coordination, lethargy, confusion, trembling hands, and bad breath. The symptoms are usually subtle and may be attributed incorrectly to other causes. This can cause delays in diagnosis or inaccurate diagnosis. The absence of an agreed standard procedure or diagnostic test is also a challenge that compounds concerns about the diagnosis of the disease. Hence, the late and inaccurate diagnosis of HE could affect the growth of the global HE therapeutics market during the forecast period.

This hepatic encephalopathy (HE) therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global hepatic encephalopathy (HE) therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the hepatic encephalopathy (HE) therapeutics market during the forecast period.

Who are the Major Hepatic Encephalopathy (HE) Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Alfasigma Spa
• ASKA Pharmaceutical Co. Ltd.
• Bausch Health Companies Inc.
• COSMO PHARMACEUTICALS NV
• Cumberland Pharmaceuticals Inc.
• Horizon Therapeutics Plc
• Lupin Ltd.
• Mallinckrodt Plc
• Norgine BV
• Rebiotix Inc.

 

This statistical study of the hepatic encephalopathy (HE) therapeutics market encompasses successful business strategies deployed by the key vendors. The hepatic encephalopathy (HE) therapeutics market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• Alfasigma Spa - The company offers rifaximin-a, a poorly absorbed and therefore safe antibiotic, used in the treatment of gastrointestinal tract disorders.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The hepatic encephalopathy (HE) therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Hepatic Encephalopathy (HE) Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the hepatic encephalopathy (HE) therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market includes the following core components:

• Research and development (R&D) and drug discovery
• Integration and product development
• Manufacturing
• Outbound logistics
• Marketing and sales
• Support services
• Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Hepatic Encephalopathy (HE) Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for hepatic encephalopathy (HE) therapeutics in North America. Market growth in this region will be faster than the growth of the market in the European and ROW regions.

The presence of the US, which is the largest market for pharmaceuticals in the world will facilitate the hepatic encephalopathy (HE) therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Product Segments in the Hepatic Encephalopathy (HE) Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The hepatic encephalopathy (HE) therapeutics market share growth by the NADs segment will be significant during the forecast period. The NADs segment will grow moderately during the forecast period. Although rifaximin is better tolerated, NADs are preferred as the first line of therapy due to the side effects associated with antibiotics, such as alterations in gut flora. NADs are also inexpensive. Hence, the demand for NAD HE therapeutics is expected to increase during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the hepatic encephalopathy (HE) therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in: 

Antibiotics market - The Market share is expected to increase by USD 4.44 billion from 2019 to 2024, and the market's growth momentum will accelerate at a CAGR of 3.03%.

Hepatic Encephalopathy (HE) Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 6.08%
Market growth 2021-2025	$ 1 billion
Market structure	Fragmented
YoY growth (%)	3.05
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 41%
Key consumer countries	US, UK, Germany, China, and Canada
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Alfasigma Spa, ASKA Pharmaceutical Co. Ltd., Bausch Health Companies Inc., COSMO PHARMACEUTICALS NV, Cumberland Pharmaceuticals Inc., Horizon Therapeutics Plc, Lupin Ltd., Mallinckrodt Plc, Norgine BV, and Rebiotix Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Hepatic Encephalopathy (HE) Therapeutics Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive hepatic encephalopathy (HE) therapeutics market growth during the next five years
• Precise estimation of the hepatic encephalopathy (HE) therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the hepatic encephalopathy (HE) therapeutics industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of hepatic encephalopathy (HE) therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch